Studies have shown that overexpression of FOS can promote tumorigenesis and chemotherapy resistance in tumors such as ovarian cancer and osteosarcoma, and that c‐FOS expression is clinically significantly correlated with osteosarcoma recurrence [17]. This evidence concerns the gene FOS and ovarian cancer.